Home > Boards > US Listed > Biotechs > Lexicon Genetics (LXRX)

Current Report Filing (8-k) Source: Edgar (US Regulatory) UNITED

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
tigertiger88 Member Profile
 
Followed By 3
Posts 1,567
Boards Moderated 0
Alias Born 01/26/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2020 7:23:07 AM
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Sci... GlobeNewswire Inc. - 11/16/2020 10:01:39 PM
Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference GlobeNewswire Inc. - 11/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/30/2020 5:11:39 PM
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update GlobeNewswire Inc. - 10/29/2020 6:00:10 AM
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020 GlobeNewswire Inc. - 10/27/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/29/2020 7:14:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/24/2020 7:13:15 AM
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness GlobeNewswire Inc. - 9/23/2020 6:43:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 4:12:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/8/2020 5:03:21 PM
Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics GlobeNewswire Inc. - 9/8/2020 4:05:10 PM
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients... GlobeNewswire Inc. - 9/4/2020 8:00:10 AM
Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtu... GlobeNewswire Inc. - 9/3/2020 6:00:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:00:51 AM
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo PR Newswire (US) - 8/3/2020 7:25:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2020 7:19:01 AM
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program GlobeNewswire Inc. - 7/30/2020 7:15:10 AM
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO GlobeNewswire Inc. - 7/30/2020 7:10:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2020 7:05:27 AM
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire Inc. - 7/30/2020 7:00:10 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 7/29/2020 5:08:32 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/29/2020 4:57:55 PM
Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020 GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes GlobeNewswire Inc. - 7/21/2020 7:00:10 AM
tigertiger88   Friday, 09/11/20 09:22:06 PM
Re: None
Post # of 641 
Current Report Filing (8-k)

Source: Edgar (US Regulatory)




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________

FORM 8-K
__________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2020

Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware 000-30111 76-0474169 (State or other jurisdiction of
incorporation or organization) (Commission File Number) (I.R.S. Employer
Identification Number)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive offices and Zip Code)

(281) 863-3000
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?




Item 2.01 Completion of Acquisition or Disposition of Assets

On September 8, 2020, Lexicon Pharmaceuticals, Inc. (the “Company”) completed the previously disclosed sale to TerSera Therapeutics LLC (“TerSera”) of the Company's XERMELO® (telotristat ethyl) product and related assets pursuant to the Asset Purchase and Sale Agreement (the “Purchase and Sale Agreement”) by and between the Company and TerSera, dated July 29, 2020, as amended by the First Amendment to Asset Purchase and Sale Agreement (the “First Amendment”), by and between the Company and TerSera, dated August 10, 2020.

The consideration paid by TerSera pursuant to the Purchase and Sale Agreement consisted of: (a) an upfront cash payment of approximately $160,400,000, including the book value of inventory, subject to working capital and other adjustments set forth in the Purchase and Sale Agreement, and (b) the following potential future contingent payments: (i) development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of XERMELO in patients with biliary tract cancer and (ii) mid-teens percentage royalty payments on net sales of XERMELO in biliary tract cancer.

The foregoing description of the Purchase and Sale Agreement and the First Amendment does not purport to be complete and is qualified in its entirety by the full text of the Purchase and Sale Agreement and the First Amendment, which are attached hereto as Exhibits 2.1 and 2.2, respectively, and are incorporated herein by reference.

In connection with the closing of the transaction, the Company’s borrowings under its Loan Agreement, dated December 4, 2017, with BioPharma Credit PLC, as collateral agent and a lender, and BioPharma Credit Investments IV Sub LP, as a lender, were repaid in full.

The representations, warranties and covenants contained in the Purchase and Sale Agreement (and the First Amendment, as applicable) were made only for the purposes of the Purchase and Sale Agreement, were made as of specific dates, were made solely for the benefit of the parties to the Purchase and Sale Agreement and the First Amendment and may not have been intended to be statements of fact but, rather, as a method of allocating risk and governing the contractual rights and relationships between the parties to the Purchase and Sale Agreement. The assertions embodied in those representations and warranties may be subject to important qualifications and limitations agreed to by the Company and TerSera in connection with negotiating their respective terms. Moreover, the representations and warranties may be subject to a contractual standard of materiality that may be different from what may be viewed as material to stockholders. For the foregoing reasons, none of the Company’s stockholders or any other person should rely on such representations and warranties, or any characterizations thereof, as statements of factual information at the time they were made or otherwise.


Item 8.01 Other Events

On September 8, 2020, the Company issued a press release announcing the closing of the Purchase and Sale Agreement with TerSera. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and incorporated herein by this reference.


Item 9.01 Financial Statements and Exhibits

(b) Pro Forma Financial Information.

The following unaudited pro forma financial statements reflecting the XERMELO asset disposition described above (as defined in Regulation S-X) are filed as Exhibit 99.2 to this Current Report and incorporated herein by reference:

Lexicon Pharmaceuticals, Inc. Unaudited Pro Forma Consolidated Balance Sheet as of June 30, 2020.


Lexicon Pharmaceuticals, Inc. Unaudited Pro Forma Condensed Consolidated Statements of Income (Loss) for the year ended December 31, 2019 and the six-months ended June 30, 2020.

(d) Exhibits

Exhibit No. Description
2.1*†

Asset Purchase and Sale Agreement, dated July 29, 2020, by and between Lexicon Pharmaceuticals, Inc. and TerSera Therapeutics LLC
2.2 —
First Amendment to Asset Purchase and Sale Agreement, dated August 10, 2020, by and between Lexicon Pharmaceuticals, Inc. and TerSera Therapeutics LLC
99.1 —
Press Release Issued by Lexicon Pharmaceuticals, Inc. on September 8, 2020
99.2 —
Pro Forma Financial Information of Lexicon Pharmaceuticals, Inc
104 — Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the U.S. Securities and Exchange Commission (the “SEC”); provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits or schedules so furnished. A list identifying the contents of all omitted exhibits and schedules can be found on page iii of Exhibit 2.1.

† In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by “[**]”) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.



Safe Harbor For Forward-Looking Statements

Statements contained in this Current Report on Form 8-K about the Company, the Purchase and Sale Agreement, the First Amendment and the transaction that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words “believes,” “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the accounting and tax treatments of the transaction; the anticipated cash and non-cash charges associated with the transaction; the ability of the Company to successfully separate the XERMELO® business from the Company’s other businesses; the commercial success of telotristat ethyl for the treatment of biliary tract cancer and the risk that future milestone and royalty payments may not be received by the Company on the terms negotiated with TerSera or at all; and such other factors as are set forth in the risk factors detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including, without limitation, the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements, unless required by law.


Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lexicon Pharmaceuticals, Inc. Date: September 11, 2020 By: /s/ Brian T. Crum Brian T. Crum
Vice President and General Counsel






Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences